AVTX
Avalo Therapeutics, Inc.
Healthcare — Biotechnology
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Strong Buy
1.1 / 5
12 analysts
$14.95
$-0.38 (-2.48%)
Target:
$45.25
(202.7%)
Price History
52-Week Range
Sign in to add AVTX to a watchlist or set price alerts.
Fundamentals
| Market Cap | $971.41M |
| P/E Ratio (TTM) | - |
| Forward P/E | -6.60 |
| EPS (TTM) | $-5.57 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -88.76% |
| Debt/Equity | 0.48 |
| Recommendation | Strong Buy 1.1 |
| Analyst Target | $45.25 |
| Analysts | 12 |
| Next Earnings | Aug 6, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 78.5 |
| Beta | 0.82 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $24.27 |
| 52-Week Low | $4.61 |
| 50-Day Avg | $15.95 |
| 200-Day Avg | $15.77 |
| Avg Volume | $1.24M |
| Volume | $1.10M |
Performance Analysis
NEUTRALAVTX presents a mixed picture with both positive and negative indicators.
~
Trading at 53% of its 52-week range.
-
RSI at 78.5 indicates overbought conditions — a pullback may be due.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
+
Wall Street consensus is "Strong Buy" from 12 analysts.
+
Average analyst target of $45.25 implies 202.7% upside.
Recent News
Loading news...
Last updated: Jun 30, 2026 21:08 UTC
Back to Screener Export Report